Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Q1 2012 Earnings Presentation

12 slides from Questcor Pharmaceuticals's earnings presentation, Apr 26, 2012

  1. Slide 1: First Quarter 2012 Conference Call

    First Quarter 2012 Conference Call NASDAQ: QCOR Exhibit 99.3 First Quarter 2012 Conference Call NASDAQ: QCOR

  2. Slide 2: Conference Call Logistics

    2 • Today’s webcast, accompanying slide presentation and archived replay is available online at • Telephone replay is available by dialing: – U.S.: 855-859-2056 – International: 404-537-3406 – Replay Passcode: 70200329 Conference Call Logistics http://ir.questcor.com/events.cfm • Today’s webcast, ac

  3. Slide 3: Safe Harbor Statement

    3 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa

  4. Slide 4: Strong First Quarter Results

    4 • 238 paid NS scripts • 1,000 paid MS scripts – Up 97% YOY • 112 paid IS scripts • Record financial performance – 4,111 vials shipped, up 105% YOY – $96.0M in net sales, up 161% YOY – $0.58 GAAP EPS (diluted), up 241% YOY Strong First Quarter Results • 238 paid NS scripts • 1,000 paid MS scripts –

  5. Slide 5: Paid Rxs NS Scripts - Strong Continued Growth

    5 Paid Rxs NS Scripts-Strong Continued Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the fo

  6. Slide 6: MS Scripts - Record of Consistent Growth

    6 Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely rel

  7. Slide 7: Monthly MS Scripts History

    7 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the c

  8. Slide 8: Shipped Vials

    Shipped Vials Q1-10 Q2-40 Q3-10 Q410 Q1-41 Q2-44 Q3-114 Q441 Q1-12 =>Shipped Vials (® QUESTCOR

  9. Slide 9: Understanding Acthar: the science of how it works

    9 • Generating more data for on-label indications – NS – MS – IS – Lupus • Investigating Acthar in new indications – Diabetic nephropathy – Autism – Traumatic brain injury – ALS – Migraine Over 40 Acthar R&D and Investigator Initiated Research Studies Understanding Acthar: the science of how it work

  10. Slide 10: Q1-2012 Financial Results

    10 Q1 – 2012 Q1 – 2011 Q1-2012 Financial Results • First quarter vials shipped: 4,111 • First quarter cash flow from operations: $40.9M • Channel inventory estimated to be higher than fourth quarter • Medicaid reserves continue to appear adequate • 798,285 shares repurchased during Q1-2012 Record Ne

  11. Slide 11: Questcor is Cash Flow Positive

    11 04/20/12 Questcor is Cash Flow Positive *After return of $107 million of cash to shareholders through share repurchases. Debt-free balance sheet Cash / ST Investments $248M* Accounts Receivable $37M *After return of $107 million of cash to shareholders through share repurchases.

  12. Slide 12: Investment Highlights

    12 Investment Highlights 12 Acthar has sustainable competitive Acthar has sustainable competitive advantages-without FDA approval risk advantages-without FDA approval risk Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need i

Questcor Pharmaceuticals — Q1 2012 Earnings Presentation on 6ix